Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 195 participants.

Also called NCT02042534

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 195 participants (enrolled count) (from the registry)
Sponsor
  • Asan Medical Center Registry lists this organization as the lead sponsor
  • Bayer Registry lists this organization as a collaborator
Registry
  • NCT NCT02042534
Other papers using this trial's data
  • Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial JAMA neurology, 2017-10-01 DOI, PubMed 28892526, PMC5710243 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02042534. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-12 (actual). Results posted on 2017-02-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
Acronym
TripleAXEL
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Warfarin
Lead sponsor
Asan Medical Center (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02042534
Content hash
cdfbe35da906d1b5a340108e831f8bf8964cab044ed4c15f5d7cb759a0b2cb69